Clinical Report: Assessment of Revvity's sFlt-1 and PlGF Assays in Preeclampsia

Background

Preeclampsia (PE) is a serious pregnancy complication affecting 2-5% of women in developed countries, associated with significant maternal and neonatal risks. The identification of reliable biomarkers such as sFlt-1 and PlGF is crucial for the early diagnosis and management of PE. Recent guidelines have emphasized the use of these biomarkers in clinical practice, yet variability in assay performance necessitates careful evaluation.

Data Highlights

Key Findings

• Imprecision estimates for the Revvity PlGF and sFlt-1 methods calculated from quality control material analysed during the evaluation were between 3.2% and 9.0% CV%.
• Median CV% for PlGF was 1.8% and for sFlt-1 was 1.1% based on clinical specimens.
• Concordance of the sFlt-1:PlGF ratio relative to manufacturer thresholds was 95.2%.
• Statistically significant concentration-dependent relative bias was observed for both assays.
• Numeric agreement between Revvity and Roche methods limits result interchangeability.

Clinical Implications

Understanding the differences in assay performance is essential for accurate diagnosis and management of preeclampsia.

Conclusion

The analytical evaluation of Revvity's sFlt-1 and PlGF assays demonstrates their precision and correlation with Roche methods.

Related Resources & Content

1. NICE, Guidance, 2022 -- PLGF-based testing to help diagnose suspected preterm pre-eclampsia
2. The Journal of Clinical Endocrinology & Metabolism, 2025 -- Assessing the sFlt-1/PlGF Ratio for Early Prediction of Preeclampsia in Patients with Gestational Diabetes Mellitus
3. the pathologist, 2026 -- Pre-eclampsia Care: Let's Make it Proactive
4. BMC Pregnancy and Childbirth, 2026 -- The use of the first trimester (AST × LDH × urea) / (platelet × hemoglobin) index in the prediction of preeclampsia
5. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy, European Heart Journal
6. Frontiers in Cardiovascular Medicine — Soluble fms-like tyrosine kinase-1 and peripartum cardiomyopathy: an exploratory meta-analysis of association and diagnostic performance
7. Overview | PLGF-based testing to help diagnose suspected preterm pre-eclampsia
8. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy | European Heart Journal | Oxford Academic